Literature DB >> 17989349

Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences.

Andrew Holt1, David J Smith, Laura Cendron, Giuseppe Zanotti, Adelio Rigo, Maria Luisa Di Paolo.   

Abstract

Human semicarbazide-sensitive amine oxidase (SSAO) is a target for novel anti-inflammatory drugs that inhibit enzymatic activity. However, progress in developing such drugs has been hampered by an incomplete understanding of mechanisms involved in substrate turnover. We report here results of a comparative study of human and bovine SSAO enzymes that reveal binding of substrates and other ligands to at least two (human) and up to four (bovine) distinct sites on enzyme monomers. Anaerobic spectroscopy reveals binding of substrates (spermidine and benzylamine) and of an imidazoline site ligand (clonidine) to the reduced active site of bovine SSAO, whereas interactions with oxidized enzyme are evident in kinetic assays and crystallization studies. Radioligand binding experiments with [(3)H]tetraphenylphosphonium, an inhibitor of bovine SSAO that binds to an anionic cavity outside the active site, reveal competition with spermidine, benzylamine, and clonidine, indicating that these ligands also bind to this second anionic region. Kinetic models of bovine SSAO are consistent with one spermidine molecule straddling the active and secondary sites on both oxidized and reduced enzyme, whereas these sites are occupied by two individual molecules of smaller substrates such as benzylamine. Clonidine and other imidazoline site ligands enhance or inhibit activity as a result of differing affinities for both sites on oxidized and reduced enzyme. In contrast, although analyses of kinetic data obtained with human SSAO are also consistent with ligands binding to oxidized and reduced enzyme, we observed no apparent requirement for substrate or modulator binding to any secondary site to model enzyme behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17989349     DOI: 10.1124/mol.107.040964

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  11 in total

1.  An improved approach to steady-state analysis of monoamine oxidases.

Authors:  Rona R Ramsay; Aldo Olivieri; Andrew Holt
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

2.  CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKCε phosphorylation and membrane translocation in sensory neurons.

Authors:  Vittorio Vellani; Chiara Sabatini; Chiara Milia; Gianfranco Caselli; Marco Lanza; Ornella Letari; Lucio Claudio Rovati; Chiara Giacomoni
Journal:  Br J Pharmacol       Date:  2019-11-07       Impact factor: 8.739

Review 3.  On the practical aspects of characterising monoamine oxidase inhibition in vitro.

Authors:  Andrew Holt
Journal:  J Neural Transm (Vienna)       Date:  2018-10-29       Impact factor: 3.575

Review 4.  Copper active sites in biology.

Authors:  Edward I Solomon; David E Heppner; Esther M Johnston; Jake W Ginsbach; Jordi Cirera; Munzarin Qayyum; Matthew T Kieber-Emmons; Christian H Kjaergaard; Ryan G Hadt; Li Tian
Journal:  Chem Rev       Date:  2014-03-03       Impact factor: 60.622

5.  From caffeine to fish waste: amine compounds present in food and drugs and their interactions with primary amine oxidase.

Authors:  Aldo Olivieri; Daniel Rico; Zhied Khiari; Gary Henehan; Jeff O'Sullivan; Keith Tipton
Journal:  J Neural Transm (Vienna)       Date:  2011-03-04       Impact factor: 3.575

6.  Isopropylnorsynephrine is a stronger lipolytic agent in human adipocytes than synephrine and other amines present in Citrus aurantium.

Authors:  Josep Mercader; Estelle Wanecq; Jian Chen; Christian Carpéné
Journal:  J Physiol Biochem       Date:  2011-02-19       Impact factor: 4.158

7.  Structure and inhibition of human diamine oxidase.

Authors:  Aaron P McGrath; Kimberly M Hilmer; Charles A Collyer; Eric M Shepard; Bradley O Elmore; Doreen E Brown; David M Dooley; J Mitchell Guss
Journal:  Biochemistry       Date:  2009-10-20       Impact factor: 3.162

8.  Novel pyridazinone inhibitors for vascular adhesion protein-1 (VAP-1): old target-new inhibition mode.

Authors:  Eva Bligt-Lindén; Marjo Pihlavisto; István Szatmári; Zbyszek Otwinowski; David J Smith; László Lázár; Ferenc Fülöp; Tiina A Salminen
Journal:  J Med Chem       Date:  2013-12-13       Impact factor: 7.446

9.  Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain.

Authors:  Flora Ferrari; Simonetta Fiorentino; Laura Mennuni; Paolo Garofalo; Ornella Letari; Stefano Mandelli; Antonio Giordani; Marco Lanza; Gianfranco Caselli
Journal:  J Pain Res       Date:  2011-04-18       Impact factor: 3.133

10.  Methylxanthines Inhibit Primary Amine Oxidase and Monoamine Oxidase Activities of Human Adipose Tissue.

Authors:  Wiem Haj Ahmed; Cécile Peiro; Jessica Fontaine; Barry J Ryan; Gemma K Kinsella; Jeff O'Sullivan; Jean-Louis Grolleau; Gary T M Henehan; Christian Carpéné
Journal:  Medicines (Basel)       Date:  2020-04-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.